Research · 10 min read
Why an Approved Indication Is Always Narrower Than the Marketing
An indication is one sentence naming exactly who the evidence covers. On these five labels every one of those sentences excludes more people than it includes — and one of them is provisional.
Key takeaways
- Every weight indication on these labels is for the drug in combination with a reduced-calorie diet and increased physical activity — a phrase appearing 25, 19 and 10 times on the three weight labels and zero times on the two diabetes labels.
- Eligibility has two doors: obesity alone, or overweight plus at least one weight-related condition. Overweight alone is not an approved population.
- The sleep apnea indication requires obesity and moderate to severe disease; the weight-brand cardiovascular indication requires a prior heart attack, stroke or peripheral arterial disease, not risk factors.
- One indication is granted under accelerated approval, and the label says continued approval may be contingent on a confirmatory trial.
- Across five labels, three state no established pediatric use, one establishes age 12 and up for weight, and one establishes age 10 and up for blood sugar only.
- A Limitations of Use paragraph appears on all three weight labels and on neither diabetes label, and says combining with another GLP-1 receptor agonist is not recommended.
Answer first: the indication is a boundary, and the advertising is a mood
Section 1 of a prescribing information document is called Indications and Usage. It is a short, legally exact statement of what a product is approved to do and in whom. Everything a company says publicly has to live inside it. Almost nothing you read about these drugs quotes it.
Reading Section 1 on all five of the labels behind the products people ask about, the pattern is consistent. Each indication names a population by a measurable criterion, pairs the drug with something else, and in three cases attaches an explicit limitation. The population is always narrower than the impression left by a landing page, and the pairing is almost never mentioned at all.
This is not a complaint about advertising. It is a practical point: the indication tells you whether the evidence behind a claim was generated in people like you, and it takes about a minute to read.
The pairing nobody quotes: every weight indication is a combination indication
All three products approved to reduce excess body weight state the same thing in the same place. The indication is not for the drug. It is for the drug in combination with a reduced-calorie diet and increased physical activity.
That phrase is not decorative. It occurs 25 times across the tirzepatide weight label, 19 times across the semaglutide weight label and 10 times across the orforglipron label. It occurs zero times on either of the two diabetes labels, which instead describe their products as an adjunct to diet and exercise — a phrase that appears 6 and 2 times on those two and zero times on the weight three. Five labels, two vocabularies, no overlap.
The trials matched the wording. Everyone in the weight trials was in a program: instruction on a reduced-calorie diet at roughly a 500 calorie daily deficit and counseling toward at least 150 minutes of physical activity a week, starting with the first dose and continuing throughout. In one trial the program was far more intensive than that.
So the approved use, and the evidence behind it, describe a drug plus a program. A page that presents the drug alone and the percentage alone has dropped half of what was studied.
The eligibility sentence has two doors, and one of them has a condition attached
The weight indications read: adults with obesity, or adults with overweight in the presence of at least one weight-related comorbid condition. Two doors. The first is a body mass index threshold on its own. The second requires the threshold and a qualifying condition — the labels' trial sections name examples such as dyslipidemia, high blood pressure, obstructive sleep apnea and cardiovascular disease.
The phrase weight-related comorbid condition appears 14, 16 and 16 times across the three weight labels and zero times on either diabetes label. It is doing real work every time.
The practical consequence is that overweight alone is not an approved population for any of these three products. Whether a given person meets the second door is a clinical judgment made by a prescriber with a history in front of them, not something a website can resolve. But knowing the door exists changes what you expect from an intake questionnaire, and it explains why a program can decline someone who is certain they qualify.
Each extra indication names its own, much smaller population
The sleep apnea approval on the tirzepatide weight label is for moderate to severe obstructive sleep apnea in adults with obesity. Not overweight with a condition — obesity. The trials behind it defined moderate to severe as at least 15 breathing events an hour on an overnight study, and required a body mass index of 30 or greater.
The cardiovascular approval on the semaglutide weight label is for adults with established cardiovascular disease and either obesity or overweight. The phrase established CV disease appears 10 times on that label, and the trial behind it defined it as a prior heart attack, a prior stroke, or peripheral arterial disease. Risk factors do not meet it. That trial also excluded anyone with a history of type 1 or type 2 diabetes.
The cardiovascular approval on the tirzepatide diabetes label requires adults with type 2 diabetes who are at high risk for those events. The two approvals on the semaglutide diabetes label require type 2 diabetes plus established cardiovascular disease, and type 2 diabetes plus chronic kidney disease, respectively.
Every one of those sentences is a gate. None of them describes a general population, and none transfers to another product on the list.
One indication on these labels is provisional, and says so
The semaglutide weight label carries a third approval that most coverage of these drugs never mentions: treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis in adults.
It is granted under accelerated approval, based on improvement of the disease and of fibrosis rather than on a long-term clinical outcome. The label states the consequence in the indication itself: continued approval for this indication may be contingent upon the verification and description of clinical benefit in a confirmatory trial. The supporting analysis was at week 72 of a 240-week trial in 800 patients, with two pathologists independently reading each liver biopsy and a third adjudicating disagreements.
That is a different kind of approval from the others on the page, and the label flags it in plain language. It is also injection-only — the tablet form of the same molecule does not carry it.
Same brand, same molecule, different approved uses
The semaglutide weight label covers two products under one brand name: an injection and a tablet. They are not approved for the same things.
The injection carries three indications — cardiovascular risk reduction, weight reduction and long-term maintenance, and the liver indication — and its weight indication extends to pediatric patients aged 12 and older with obesity. The tablet carries two indications, both adults only, and no liver indication.
The same label then adds a section on type 2 diabetes that is worth reading in full if you are considering the tablet. It states the tablet has not been studied for weight reduction in adults with type 2 diabetes and obesity or overweight. It reports that average blood levels of the drug were similar between tablet and injection in people without type 2 diabetes, but lower with the tablet in people with it. And it states that given that difference and higher variability with the tablet across all populations, some patients with type 2 diabetes taking the tablet may end up below the therapeutic range.
One brand name, one molecule, two forms, and a documented gap between them for a large group of patients.
The pediatric row is the clearest example of how specific this gets
Section 8.4 on five labels, read in full rather than counted. Three of them state that nothing has been established in pediatric patients: the tirzepatide weight label and the orforglipron label both say safety and effectiveness have not been established, and the semaglutide diabetes label says safety and efficacy have not been established.
The two that do establish a pediatric use establish different ones. The semaglutide weight label establishes the injection for weight reduction in patients 12 and older with obesity, supported by a 68-week trial in 201 patients, and notes that those patients had higher rates of gallstones, gallbladder inflammation, low blood pressure, rash and hives than adults on the same drug. The tirzepatide diabetes label establishes use in patients 10 and older for glycemic control only, supported by a 30-week trial in 99 patients, and notes higher rates of vomiting, abdominal pain and low blood sugar than in adults.
So across five labels: three not established, one established at 12 for weight, one established at 10 for blood sugar. Different ages, different purposes, different safety notes. A sentence about what these drugs are approved for in teenagers is wrong more often than not.
Limitations of Use exist on three labels and not the other two
There is a subsection that appears immediately under the indication on three of these labels and nowhere on the other two: Limitations of Use. It occurs 3 times on the tirzepatide weight label, 3 times on the orforglipron label, 2 times on the semaglutide weight label, and 0 times on either diabetes label.
What it says on all three is a version of the same thing: taking the product together with another GLP-1 receptor agonist is not recommended, and in two cases the wording also covers other products containing the same molecule. That is the label anticipating a specific real-world behavior — stacking, or overlapping a brand product with a compounded one — and saying no to it in the section that carries the most legal weight on the page.
Anyone comparing programs should know this line exists, because it is the label's own answer to a question intake forms ask and marketing pages rarely address.
How to use this in about a minute
Open the prescribing information for the product a program is offering and read Section 1 before anything else. It is usually under 400 words. Ask three questions of it. Does it name a population you are actually in, by the criterion it uses rather than the one you assume? Does it pair the drug with something — a diet and activity program, a background therapy — that the offer in front of you does not mention? And is there a Limitations of Use paragraph underneath it?
Then check whether the claim you have been shown matches the indication you just read. A weight percentage attached to a cardiovascular claim, a sleep apnea result attached to a general obesity offer, or a tablet described using an injection's approvals are all mismatches you can catch in that minute.
None of this is about catching anyone out. It is that the indication is the only sentence in the whole ecosystem that had to be true about who the evidence covers, and it is sitting in public, unread.
Sources
- ZEPBOUND (tirzepatide) injection — full prescribing information, Sections 1, 8.4 and 14The weight and obstructive sleep apnea indications and their exact populations; the 25 occurrences of the reduced-calorie diet phrase and 14 of the weight-related comorbid condition phrase; the three Limitations of Use occurrences and their wording on other tirzepatide-containing products and other GLP-1 receptor agonists; the sleep apnea entry criteria of at least 15 events an hour and a body mass index of 30 or greater; the roughly 500 calorie deficit and 150 minute weekly activity program given to all trial patients; and the Section 8.4 statement that safety and effectiveness have not been established in pediatric patients.
- WEGOVY (semaglutide) injection and tablet — full prescribing information, Sections 1, 8.4, 8.6 and 14.4The separate indication lists for injection and tablet; the cardiovascular indication requiring established cardiovascular disease and the trial's definition of it; the liver indication, its accelerated approval status and the confirmatory-trial sentence; the week 72 analysis of a 240-week trial in 800 patients with independent biopsy readings; the 19 occurrences of the reduced-calorie diet phrase and 16 of the weight-related comorbid condition phrase; the two Limitations of Use occurrences; the Section 8.4 pediatric establishment at age 12 and older, its 68-week 201-patient trial and the higher pediatric rates of cholelithiasis, cholecystitis, hypotension, rash and urticaria; and the Section 8.6 statements about the tablet in patients with type 2 diabetes.
- FOUNDAYO (orforglipron) tablet, film coated — full prescribing information, Sections 1 and 8.4The single weight indication and its population; the 10 occurrences of the reduced-calorie diet phrase and 16 of the weight-related comorbid condition phrase; the three Limitations of Use occurrences stating that concomitant use with another GLP-1 receptor agonist is not recommended; and the Section 8.4 statement that safety and effectiveness have not been established in pediatric patients.
- MOUNJARO (tirzepatide) injection — full prescribing information, Sections 1 and 8.4The glycemic control and cardiovascular indications in adults with type 2 diabetes; the adjunct to diet and exercise phrasing at 6 occurrences with zero occurrences of the reduced-calorie diet phrase; the absence of any Limitations of Use subsection; and the Section 8.4 establishment of use in patients 10 years and older for glycemic control only, its 30-week 99-patient trial, and the higher pediatric rates of vomiting, abdominal pain and hypoglycemia.
- OZEMPIC (semaglutide) injection — full prescribing information, Sections 1 and 8.4The three indications, each requiring type 2 diabetes and, for two of them, established cardiovascular disease or chronic kidney disease; the adjunct to diet and exercise phrasing at 2 occurrences with zero occurrences of the reduced-calorie diet phrase; the absence of any Limitations of Use subsection; and the Section 8.4 statement that safety and efficacy have not been established in pediatric patients.
Frequently asked questions
What does it mean that these drugs are approved 'in combination with a reduced-calorie diet and increased physical activity'?
It means the approved use is the drug plus a program, not the drug on its own. The phrase appears 25, 19 and 10 times across the three weight labels and zero times on either diabetes label, which use a different phrase. It matched the trials, where everyone received instruction on a reduced-calorie diet and physical activity counseling from the first dose onward. A result quoted without that context has dropped part of what was studied.
Am I eligible if I am overweight but do not have obesity?
The indication has two doors: obesity on its own, or overweight together with at least one weight-related condition. Overweight alone is not an approved population for any of the three weight products. What counts as a qualifying condition is a clinical judgment — the labels' trial sections give examples such as dyslipidemia, high blood pressure, obstructive sleep apnea and cardiovascular disease — and only a prescriber who has your history can make it.
Why is one of the approvals described as provisional?
One indication on the semaglutide weight label, for a liver condition with moderate to advanced fibrosis, was granted under accelerated approval based on improvement of the disease on biopsy rather than on a long-term clinical outcome. The label states within the indication itself that continued approval may be contingent on verification and description of clinical benefit in a confirmatory trial. The supporting analysis was at week 72 of a 240-week trial in 800 patients.
Are these drugs approved for teenagers?
It depends entirely on which product. Reading Section 8.4 on five labels: three state that nothing has been established in pediatric patients — two using the words safety and effectiveness, one safety and efficacy. One establishes an injection for weight reduction in patients 12 and older with obesity, based on a 68-week trial in 201 patients. One establishes a different product in patients 10 and older, for blood sugar control only, based on a 30-week trial in 99 patients. Both of the labels with a pediatric use flag adverse reactions that occurred more often in young patients than in adults.
What is a Limitations of Use paragraph?
A short statement printed directly under the indication that narrows it further. It appears on the three weight labels and on neither diabetes label. On all three it says that taking the product together with another GLP-1 receptor agonist is not recommended, with two of them also covering other products containing the same molecule. It is the label's own answer to whether these can be combined or overlapped.
Is the tablet form of semaglutide the same as the injection?
For weight purposes they are separate products with separate approvals on the same label. The injection carries three indications and extends to patients 12 and older; the tablet carries two, adults only. The label also states that the tablet has not been studied for weight reduction in adults with type 2 diabetes and obesity or overweight, that average blood levels were lower with the tablet in people with type 2 diabetes, and that some of those patients may end up below the therapeutic range on the tablet.